期刊文献+

肝硬化腹水合并低钠血症的治疗探讨 被引量:4

下载PDF
导出
摘要 目的探讨肝硬化腹水引起低钠血症的原因及疗效。方法将中、重度低钠血症患者共57例随机分为限钠组28例,其中中度缺钠者20例,重度缺钠者8例;不限钠组29例,其中中度缺钠者19例,重度缺钠者10例,限钠组患者每日进低盐饮食,不限钠组除进正常人含钠食物外,根据血浆钠检测结果,静脉补充钠盐(配制成3%氯化钠溶液)3~9g/d,连续3~7d,血钠恢复正常后停用,根据血钠检测值可再次重复使用。其余治疗方法两组相同。结果限钠组28例患者死亡20例,死亡率71.43%,不限钠组29例患者死亡12例,死亡率41.38%。经χ2检验P<0.05(χ2=4.08),差异有显著性。结论不限钠组治疗效果明显优于限钠组。
作者 刘建纲
出处 《中国现代药物应用》 2010年第4期99-99,共1页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献3

二级参考文献16

  • 1Decaux G.Difference is solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985[].Journal of Laboratory and Clinical Medicine.2001
  • 2Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis[].Journal of Hepatology.2000
  • 3Gines P,Jimenez W.Aquaretic agent: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
  • 4Gines P,Jimenez W.Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
  • 5Bosch-Marce M,Jimenez W,Angeli P,et al.Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention[].Gastroenterology.1995
  • 6Bosch-Marce M,Poo JL,Jimenez W,et al.Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention[].Journal of Pharmacology and Experimental Therapeutics.1999
  • 7Borroni G,Maggi A,Sangiovanni A,et al.Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients[].Digestive and Liver Disease.2000
  • 8Serradeil-Le-Gal C.Nonpeptide antagonists for vasopressin receptors.Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist[].Advances in Experimental Medicine and Biology.1998
  • 9Yamamura Y,Ogawa H,Yamashita H,et al.Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist[].British Journal of Pharmacology.1992
  • 10Gulberg V,Moller S,Henriksen JH,et al.Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure[].Gut.2000

共引文献14090

同被引文献37

  • 1李玉丹,金勇.肝性脑病62例临床分析[J].临床荟萃,2006,21(13):936-936. 被引量:1
  • 2于红卫,冯岩梅,孟庆华.能量代谢测定系统(代谢车)临床应用的研究进展[J].中国全科医学,2006,9(21):1817-1818. 被引量:7
  • 3文毅,陈宇宁,陈艺.肝硬化腹水合并低钠血症42例分析[J].现代医院,2007,7(3):50-50. 被引量:3
  • 4Wong VW, Wong GL, Yu J, et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese [J]. Am J Gastroenterol,2010,105(1):132-138.
  • 5Donaghy A. Issues of malnutrition and bone disease in patients with cirrhosis[J].J Gastroenterol Hepatol,2002,17(4):462 -466.
  • 6Gundling F, Schepp W. Nutrition in liver cirrhosis: diagnostic aspects and treatment[J]. Dtsch Med Wochenschr, 2008,133 (16) :846-851.
  • 7Chang WT,Ker CG. Hung HC,et al. Albumin and prealbumin may predict retinol status in patients with liver cirrhosis[J]. Hepatogastroenterology, 2008,55(86/87) : 1681-1685.
  • 8Moreno Villares JM. Parenteral nutrition-associated liver disease [J]. Nutr Hosp,2008,23(2) :25-33.
  • 9Morgan MY, Madden AM, Jennings G. et al. Two component models are of limited value for the assessment of body composition in patients with cirrhosis[J]. Am J Clin Nutr, 2006,84(5):1151-1162.
  • 10Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial [ J ].Hepatology, 9008,48(2):557-566.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部